KMT2A and leukemia: The presence of RAS mutations at diagnosis detected in 63.9% of patients as well as gene and protein expression data supporting the presence of an active RAS-related profile in patients harbouring RAS mutations prompted us to explore the possibility of targeting the RAS pathway as a potential therapeutic approach in BCP-ALL MLL-AF4+ RASmut leukaemia.